The efffect of herbal and animal omega-3 fatty acids on polycystic ovary syndrome

Clinical and metabolic response to herbal and animal omega-3 fatty acids supplementation in women with poly cystic ovary syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016041612438N19

Enrollment

105

Registered

2016-05-05

Start date

2016-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovarian syndrome. Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group 1: Herbal Omega-3 fatty acid capsule,2 times per day for 12 weeks orally. Intervention 2: Intervention group 2: Fish oil Omega-3 fatty acid capsule,2 times per day

Treatment - Drugs

Placebo

Intervention group 1: Herbal Omega-3 fatty acid capsule,2 times per day for 12 weeks orally.

Intervention group 2: Fish oil Omega-3 fatty acid capsule,2 times per day for 12 weeks orally.

Control group:placebo capsule,2 times per day for 12 weeks orally.

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with PCOS according to Rotterdam criteria; higher than 5 years of their disease; aged 18 to 40 years. Exclusion criterion: unwillingness to cooperate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Follicular- stimulating hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Acne. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Lipid profile. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Hair loss. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;DHEAs. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.	—

Measure

Time frame

Hirsutism. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Insulin resistance. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Insulin. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Testosterone. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Prolactin. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Follicular- stimulating hormone. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Acne. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;Lipid profile. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.;Hair loss. Timepoint: Baseline and End-of-trial. Method of measurement: Observation.;DHEAs. Timepoint: Baseline and End-of-trial. Method of measurement: Blood sample.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mohsen Taghizadeh

Kashan University of Medical Sciences

mohsenta44@yahoo.com+98 31 5554 0021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026